The <Emphasis Type="Italic">in vitro</Emphasis>effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
(1) Translational Oncology Research Centre, Department of Histopathology, Queen Alexandra Hospital, Portsmouth, UK;(2) Mayday University Hospital, Croydon, UK;(3) Richards Hospital, Chichester, UK
Abstract:
Background
Activation of the epidermal growth factor receptor (EGFR) triggers downstream signaling pathways that regulate many cellular
processes involved in tumour survival and growth. Gefitinib ('Iressa') is an orally active tyrosine kinase inhibitor (TKI)
targeted to the ATP-binding domain of EGFR (HER1; erbB1).